(RTTNews) - IN8bio, Inc. (INAB) announced the launch of its next-generation Gamma-Delta T-cell engager or TCE platform INB-600, designed to overcome the limitations of existing Gamma-Delta TCE ...

A new study published in Cell Reports Medicine reveals critical insights into the role of gamma-delta T cells across 33 cancer types, shedding light on their potential as clinical biomarkers and ...

The "Global Gamma Delta T Cell Cancer Therapy Market Opportunity & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. After vicennium of futuristic T cells ...

-Data demonstrate characteristics essential for treatment of autoimmune diseases, including robust tissue homing and complete CD19+ B cell depletion in secondary lymphoid tissue -Results highlight the ...

A new study published in Cell Press reveals critical insights into the role of gamma-delta T cells across 33 cancer types, shedding light on their potential as clinical biomarkers and therapeutic ...

− Acquisition Adds Adaptate’s Novel Antibody-based γδ T-cell Engager Platform to Takeda’s Immuno-oncology Portfolio Built Around the Innate Immune System − Successful Multi-year R&D Partnership ...

ADI-001 is an allogeneic gamma delta CAR T-cell therapy that targets the B-cell antigen CD20. The Food and Drug Administration (FDA) has granted Fast Track designation to ADI-001 for the treatment of ...

EDINBURGH, Scotland, Aug. 28, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic ...

Natalie Mount Chief Executive Officer, Cytospire Series A financing led by 4BIO Capital, with major new investors Servier Ventures, Sound Bioventures, British Business Bank and Criteria Bio Ventures, ...